ReviewJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2010
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.
Review in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 108 citations in OpenAlex.
- Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.Pediatric pulmonology · 2011Trial
- Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2011Trial
- Applications of AI/ML in accelerating the development of pulmonary drug delivery system.Acta pharmaceutica Sinica. B · 2026Review
- Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations.BMC pulmonary medicine · 2020Observational
- Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis.Scientific reports · 2018Article
- A smartphone application for reporting symptoms in adults with cystic fibrosis: protocol of a randomised controlled trial.BMJ open · 2018Article
- Evaluation of Food Insecurity in Adults and Children With Cystic Fibrosis: Community Case Study.Frontiers in public health · 2018Article
- What can the CF registry tell us about rare CFTR-mutations? A Belgian study.Orphanet journal of rare diseases · 2017Article
- Improving the care of patients with cystic fibrosis (CF).BMJ open quality · 2017Article
- Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.The Lancet. Respiratory medicine · 2016Article
- Association Between Outcomes and Demographic Factors in an Azeri Turkish Population With Cystic Fibrosis: A Cross-Sectional Study in Iran From 2001 Through 2014.Iranian Red Crescent medical journal · 2016Article
- Chest CT abnormalities and quality of life: relationship in adult cystic fibrosis.Annals of translational medicine · 2016Article
- Yoga Therapy in Children with Cystic Fibrosis Decreases Immediate Anxiety and Joint Pain.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Observational
- Burkholderia cepacia complex: clinical course in cystic fibrosis patients.BMC pulmonary medicine · 2015Article
- Yoga as a Therapy for Adolescents and Young Adults With Cystic Fibrosis: A Pilot Study.Global advances in health and medicine · 2015Article
- The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.Oman medical journal · 2015Article
- Higher mobility scores in patients with cystic fibrosis are associated with better lung function.Pulmonary medicine · 2015Observational
- Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients.CPT: pharmacometrics & systems pharmacology · 2014Article
- Voice disorder in cystic fibrosis patients.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
Abstract
Cystic fibrosis (CF) is a life-shortening disease with significant morbidity. Despite overall improvements in survival, patients with CF experience frequent pulmonary exacerbations and declining lung function, which often accelerates during adolescence. New treatments target steps in the pathogenesis of lung disease, such as the basic defect in CF (CF Transmembrane Conductance Regulator [CFTR]), pulmonary infections, inflammation, and mucociliary clearance. These treatments offer hope but also present challenges to patients, clinicians, and researchers. Comprehensive assessment of efficacy is critical to identify potentially beneficial treatments. Lung function and pulmonary exacerbation are the most commonly used outcome measures in CF clinical research. Other outcome measures under investigation include measures of CFTR function; biomarkers of infection, inflammation, lung injury and repair; and patient-reported outcomes. Molecular diagnostics may help elucidate the complex CF airway microbiome. As new treatments are developed for patients with CF, efforts should be made to balance treatment burden with quality of life. This review highlights emerging treatments, obstacles to optimizing outcomes, and key future directions for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.